Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
Bitcoin topped the $13,000 level Wednesday, rallying to its highest price since January 2018.Bitcoinread more
Wayfair drew backlash and calls from some customers for a boycott after employees protested the company's apparent sale of $200,000 of mattresses and bunk beds destined for a...Retailread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
During the foreclosure crisis, investors transformed the single-family home rental market into a formally managed asset class. Now they want new homes.Real Estateread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
The shutdown of the fire-damaged Philadelphia Energy Solutions refining complex could send gasoline prices higher across the U.S., but particularly in the mid-Atlantic region...Market Insiderread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
AstraZeneca's chief executive Pascal Soriot said "execution risks" to another Pfizer bid over tax inversion remain, as he announced better-than-expected results.
He argued that such risks were partly behind the substantial price tag of £59-plus per share, which the company wanted to start discussions with Pfizer earlier in the year.
Tax inversion, one of the main drivers behind the Pfizer bid, has come under the spotlight in the U.S., with legislation backed by President Barack Obama that could retroactively wipe out the benefits of inversion being debated.
Shire, another U.K. pharma company which is being bought by the U.S.'s AbbVie, partly for tax inversion purposes, secured a £500 million ($844 million) break clause because of concerns over possible execution risks.
AstraZeneca claimed to have "one of the most exciting pipelines" in the pharmaceutical industry, as the U.K. pharma giant reported second-quarter revenue rose by 4 percent.
The company stepped into a glare of publicity this year when its management battled with Pfizer, the biggest pharmaceuticals company in the world, for control of the company. Pfizer is now excluded from making a further approach until November under U.K. law (although it may be able to open talks earlier if AstraZeneca makes the first move).
The company has now raised its forecasts for earnings and sales for the year, after a better-than-expected revenue rise of 4 percent to $6.45 billion in the second quarter. Core earnings were up 8 percent at $1.30 a share, higher than the $1.10 expected on average by analysts.
Management are under pressure to prove they can deliver as much as shareholders would have got from the £55 per share offered by Pfizer. AstraZeneca's share price closed at £43.57 Wednesday, down from the peak of £48.23 reached during the bid battle with Pfizer.
The pharma giant announced it is buying Almirall's lung medicines in a deal worth up to $2.1 billion on Wednesday.
- By CNBC's Catherine Boyle